Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;53(1):235-239.
doi: 10.1007/s11239-021-02521-4. Epub 2021 Jul 8.

Apixaban and rivaroxaban anti-Xa level utilization for guidance of administration of andexanet alfa: a case series

Celia Morton  1 , Annette Lista  2 , Nicholas Jakowenko  2 , Eric Salazar  3 , Kevin R Donahue  2
Affiliations

Apixaban and rivaroxaban anti-Xa level utilization for guidance of administration of andexanet alfa: a case series

Celia Morton et al. J Thromb Thrombolysis. 2022 Jan.

Abstract

Background: Andexanet alfa, a modified recombinant factor Xa (FXa), was FDA approved in 2018 for anticoagulant reversal in patients with life-threatening bleeding associated with FXa inhibitors (FXaI). The ANNEXA-4 investigators administered andexanet alfa to patients within an 18-h from last dose of oral FXaI. In practice, time from last dose is often unknown. Previous studies have shown that clearance of these agents may be impaired by renal and hepatic dysfunction, as well as drug-drug interactions. Decision for use of andexanet alfa is also complicated by its high cost, limited drug availability, and thrombotic risk. This study aimed to describe the utility of anti-Xa DOAC levels as a decision point to administer andexanet alfa.

Methods: This is a case series of four patients with an anti-Xa DOAC level that received andexanet alfa for oral FXaI reversal in the setting of life-threatening bleeding or prior to procedure.

Results: Four patients were included in the study. Two patients had a known time since last dose of oral FXaI. All patients had a detectable anti-Xa DOAC levels prior to administration of andexanet alfa. Two patients had levels within the peak range, one patient had a level below the peak range, and one patient had a level above the peak range. Andexanet alfa was administered after anti-Xa DOAC level return in all patients.

Conclusion: In our case series, obtaining anti-Xa DOAC levels prior to administration of andexanet alfa was achievable and facilitated use of reversal agents in patients with major bleeding or emergent procedural need.

Keywords: Anti-Xa; Anticoagulants; Factor Xa inhibitors; Hemorrhage; Reversal.

PubMed Disclaimer

References

    1. Chai-Adisaksopha C, Hillis C, Isayama T, Lim W, Iorio A, Crowther M (2015) Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost 13(11):2012–2020 - DOI
    1. Fernando SM, Mathew R, Hibbert B et al (2020) New-onset atrial fibrillation and associated outcomes and resource use among critically ill adults-a multicenter retrospective cohort study. Crit Care 24(1):15 - DOI
    1. Jakowenko N, Nguyen S, Ruegger M, Dinh A, Salazar E, Donahue KR (2020) Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system. Thromb Res 196:276–282 - DOI
    1. Lopez CN, Succar L, Varnado S, Donahue KR (2021) Direct oral to parenteral anticoagulants: strategies for inpatient transition. J Clin Pharmacol 61:32–40 - DOI
    1. Billoir P, Barbay V, Joly LM, Fresel M, Chrétien MH, Le Cam DV (2019) Anti-Xa oral anticoagulant plasma concentration assay in real life: rivaroxaban and apixaban quantification in emergency with LMWH calibrator. Ann Pharmacother 53(4):341–347 - DOI

LinkOut - more resources